- Home
- MTVA
MTVA
METAVIA INC
as 01-17-2025 4:00pm EST
Stocks
MetaVia Inc Formerly NeuroBo Pharmaceuticals Inc is a clinical-stage biotechnology company focused predominantly on developing and commercializing novel pharmaceuticals to treat cardiometabolic diseases. The company has two primary programs focused on the treatment of metabolic dysfunction-associated steatohepatitis (MASH), and obesity. Its product pipeline includes DA-1241 which is a novel G-Protein-Coupled Receptor 119 (GPR119) and DA-1726 which is a novel oxyntomodulin (OXM) analog. The company also has four legacy therapeutics programs designed to impact a range of indications in viral, neurodegenerative, and cardiometabolic diseases: ANA001, NB-01, NB-02, and Gemcabene.
| Founded: | 2014 | Country: | United States |
| Employees: | N/A | City: | CAMBRIDGE |
| Market Cap: | 18.9M | IPO Year: | N/A |
| Target Price: | $12.00 | AVG Volume (30 days): | 337.7K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 1 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -4.29 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.51 - $6.75 | Next Earning Date: | 11-07-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest METAVIA INC News
MTVA Breaking Stock News: Dive into MTVA Ticker-Specific Updates for Smart Investing
Zacks Small Cap Research
6 days ago
Zacks Small Cap Research 2024 Initiations and Best Ideas for 2025
PR Newswire
9 days ago
MetaVia to Hold Advisory Committee Meeting at the 9th Annual MASH-TAG 2025 Conference
Zacks Small Cap Research
a month ago
MTVA: Compelling Data for DA-1241 in Phase 2a MASH Trial…
PR Newswire
a month ago
MetaVia to Participate in the 9th Annual MASH-TAG 2025 Conference After Releasing Positive Top-Line Results From Its Phase 2a Clinical Trial of DA-1241 in Patients with Presumed MASH
PR Newswire
a month ago
MetaVia Announces Positive Top-Line Results From Its Phase 2a Clinical Trial of DA-1241 in Patients with Presumed MASH
ACCESSWIRE
2 months ago
Winter 2024 Investor Summit Virtual: Q4 Presentations Now Available for On-Demand Viewing
GlobeNewswire
2 months ago
Presenting on the Emerging Growth Conference 77 Day 1 on December 4th Register Now
Zacks Small Cap Research
2 months ago
MTVA: NeuroBo Becomes MetaVia; Topline Results for Phase 2a Trial of DA-1241 in MASH Expected in December 2024…
Compare MTVA vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "MTVA METAVIA INC - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.